Market Size of CINV Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
CINV Treatment Market Analysis
The CINV treatment market studied was projected to grow with a CAGR of nearly 5.8% over the forecast period. The major factors attributing to the growth of the market are the increasing prevalence of cancer and rising research and development activities for cancer. According to the National Institutes of Health (NIH), in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth. However, the lack of awareness of the available drugs is the major drawback for market growth.
CINV Treatment Industry Segmentation
As per the scope of the report nausea and vomiting are the two most common side effects coupled with cancer chemotherapy and are described to as chemotherapy-induced nausea and vomiting. This report is segmented by Drug Type, by End-User, and by Geography.
| By Drug Type | |
| 5-HT3 inhibitors | |
| NK1 inhibitors | |
| Others |
| By End-User | |
| Hospitals | |
| Specialty Clinics | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
CINV Treatment Market Size Summary
The CINV treatment market is poised for significant growth, driven by the increasing prevalence of cancer and heightened research and development activities within the oncology sector. The market's expansion is further supported by substantial investments from biotechnology and pharmaceutical companies, although a notable challenge remains in the form of limited awareness regarding available treatment options. As chemotherapy becomes more prevalent, the associated side effects, such as nausea and vomiting, necessitate the use of CINV treatments, thereby fueling market demand. The proliferation of oncology clinics also contributes to the market's upward trajectory.
North America is anticipated to lead the CINV treatment market throughout the forecast period, attributed to the presence of key industry players, a high incidence of cancer, and a robust healthcare infrastructure. The availability of branded drugs and supportive government initiatives further bolster the region's market position. The United States, in particular, holds a significant share due to its growing geriatric population and increasing patient base. The market is moderately competitive, with major companies like Merck & Co., Inc., GlaxoSmithKline plc, and Heron Therapeutics, Inc. playing pivotal roles in shaping the landscape.
CINV Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Cancer
-
1.2.2 Rising Research and Development Activities for Cancer Treatments
-
-
1.3 Market Restraints
-
1.3.1 Lack of Awareness of the available Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Drug Type
-
2.1.1 5-HT3 inhibitors
-
2.1.2 NK1 inhibitors
-
2.1.3 Others
-
-
2.2 By End-User
-
2.2.1 Hospitals
-
2.2.2 Specialty Clinics
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
CINV Treatment Market Size FAQs
What is the current CINV Treatment Market size?
The CINV Treatment Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in CINV Treatment Market?
Merck & Co., Inc., Heron Therapeutics, Inc, Helsinn Holding S.A, GlaxoSmithKline plc (Tesaro, Inc) and Novartis AG (Sandoz) are the major companies operating in the CINV Treatment Market.
